Indications for combination anti-inflammatory therapy
Polyarticular flare
Severe pain with functional impairment
Combination options
NSAID plus colchicine
Avoid if renal impairment and dehydration
Monitor GI intolerance
Oral steroid plus colchicine
Monitor glucose
Interaction review
Refractory flare options
Interleukin-1 blockade specialist pathway
Consider when NSAIDs colchicine and steroids contraindicated
Infection exclusion required before initiation
Analgesia adjuncts
Analgesia adjuncts
Acetaminophen
650 to 1000 mg PO every 6 to 8 hours as needed
Maximum 3000 mg per day in most adults
Short-term opioid pathway
Consider only for severe pain with contraindications to anti-inflammatories
Avoid co-prescribing sedatives
Special Populations
Pregnancy
Pregnancy
Diagnostic considerations
Gout in pregnancy is uncommon
Secondary causes consideration
Medication safety
NSAIDs generally avoided in third trimester
Systemic corticosteroids often preferred for acute flare
Care pathway
Obstetrics involvement for medication selection
Infection exclusion remains priority
Geriatric
Geriatric
Presentation considerations
Polyarticular involvement more likely
Fever may be blunted
Medication risk
Higher NSAID GI and renal toxicity risk
Higher colchicine myopathy risk
Strategy
Lower threshold for intra-articular steroid after infection excluded
Dose adjustment based on eGFR and frailty
Pediatrics
Pediatrics
Epidemiology
Acute gout is rare
Secondary causes more likely than primary gout
Secondary causes
Inborn errors of metabolism
Hematologic malignancy or chemotherapy
Care pathway
Early specialty consultation
Weight-based dosing specialist guidance for colchicine and NSAIDs
Background
Epidemiology
Epidemiology
Disease burden
Common inflammatory arthritis in adults
Increasing prevalence with age and cardiometabolic disease
Risk factor clustering
Hyperuricemia association with CKD and diuretics
Alcohol association with flare risk
Sex distribution
Higher prevalence in males prior to older age groups
Pathophysiology
Pathophysiology
Core mechanism
Hyperuricemia leading to MSU crystal formation
Crystal deposition in joints and periarticular tissues
Inflammatory cascade
NLRP3 inflammasome activation
IL-1 mediated neutrophilic inflammation
Flare dynamics
Rapid onset with intense synovitis
Spontaneous resolution trend over days to weeks without treatment
Therapeutic Considerations
Therapeutic considerations
Timing
Earlier anti-inflammatory therapy associated with faster symptom control
Colchicine highest benefit when started early in flare
Urate-lowering therapy during flare
Continue ongoing urate-lowering therapy during flare to avoid rebound
Initiation of urate-lowering therapy can occur during flare with anti-inflammatory coverage when indicated
Treat-to-target principles
Serum urate target < 0.36 mmol/L for most patients
Serum urate target < 0.30 mmol/L for tophaceous disease
Patient Discharge Instructions
copy discharge instructions
copy discharge instructions
Diagnosis explanation
Likely gout flare based on symptoms and exam
Joint infection is a different condition that can look similar
Medications
Take prescribed anti-inflammatory exactly as directed
Do not stop long-term urate-lowering medication during a flare unless told to by your clinician
Self-care
Rest the joint
Ice 10 to 20 minutes at a time as needed
Hydration
Return to ED now for
Fever
Rapidly worsening redness spreading beyond the joint
New severe weakness or fainting
Inability to move the joint at all
New numbness or severe pain out of proportion
Follow-up
Follow up with primary care within 3 to 7 days
Discuss long-term urate management and prevention plan
If frequent flares, rheumatology referral discussion
References
Guidelines and evidence sources
Guidelines and evidence sources
American College of Rheumatology 2020 Guideline for the Management of Gout
Strong recommendations for flare therapy options including colchicine NSAIDs or glucocorticoids
Recommendations to continue urate-lowering therapy during flares
EULAR 2016 updated recommendations for gout management
Flare options include colchicine NSAIDs and oral or intra-articular steroids
Interleukin-1 blocker consideration for refractory flares with contraindications
Janssens 2010 diagnostic rule for acute gout in primary care
Seven-variable clinical prediction rule with probability strata
Use as adjunct when aspiration unavailable
Imaging evidence summaries
Meta-analyses comparing DECT and ultrasound diagnostic performance for gout
Ultrasound double contour sign and tophus features as supportive findings
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.